Anthony V. D'Amico
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anthony V. D'Amico has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Ming-Hui Chen
Department of Statistics, University of Connecticut, Storrs
19 shared publicationsMarian Loffredo
Department of Radiation Oncology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA
8 shared publications- Phillip W. Kantoff
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
8 shared publications Michelle H. Braccioforte
Prostate Cancer Foundation of Chicago, Westmont, Illinois
7 shared publicationsAndrew A. Renshaw
Department of Pathology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA
5 shared publicationsBrian J. Moran
Prostate Cancer Foundation of Chicago, Westmont, Illinois
5 shared publications
Latest Publications
- Open Access
- 1 May 2025
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 11 (5) , 502
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk
Importance: Whether the conventional 1.5-month to 2.0-month time interval following radical prostatectomy (RP) for prostate cancer (PC) is sufficient to accurately document a persistent prostate-specific antigen (PSA) remains unanswered.Objective: To evaluate the time necessary to accurately document a persistent PSA level after RP.Design, Setting, and Participants: This cohort study evaluated whether a significant interaction existed between (1) a pre-RP PSA level greater than 20 ng/mL vs 20 ng/mL or less and (2) persistent PSA vs undetectable PSA after RP on PC-specific mortality (PCSM) risk and all-cause mortality (ACM) risk, adjusting for known PC prognostic factors, age at RP, year of RP, and the time-dependent use of post-RP radiation therapy (RT) and androgen deprivation therapy (ADT). Whether an increasing persistent PSA level was associated with a worse prognosis was also investigated. Patients with T1N0M0 to T3N0M0 PC treated with RP between 1992 and 2020 at 2 academic centers were included. Follow-up data were collected until November 2023. Data were analyzed from July 2024 to January 2025.Exposure: RP.Main Outcomes and Measures: Adjusted hazard ratio (aHR) of ACM and PCSM risk.Results: Of 30 461 patients included in the discovery cohort, the median (IQR) age was 64 (59-68) years; of 12 837 patients included in the validation cohort, the median (IQR) age was 59 (54-64) years. Compared with patients with undetectable PSA, among patients with persistent PSA, a pre-RP PSA level greater than 20 ng/mL vs 20 ng/mL or less was significantly associated with reduced ACM risk (aHR, 0.69; 95% CI, 0.51-0.91; P = .01; P for interaction < .001) and PCSM risk (aHR, 0.41; 95% CI, 0.25-0.66; P < .001; P for interaction = .02). This result remained after adjustment for prostate volume and was confirmed in the validation cohort for PCSM risk and may represent a higher proportion of patients with a pre-RP PSA greater than 20 ng/mL vs 20 ng/mL or less who could have reached an undetectable PSA level if additional time for PSA assessment occurred before initiating post-RP therapy for presumed persistent PSA. Notably, there was more frequent and a shorter median time to post-RP RT plus ADT or ADT use in patients with a pre-RP PSA greater than 20 ng/mL (244 of 446 [54.7%] at a median [IQR] of 2.68 [1.51-4.40] months) vs 20 ng/mL or less (338 of 972 [34.8%] at a median [IQR] of 3.30 [2.00-5.39] months). These treatment times were shorter than the times to an undetectable PSA in observed patients (median [IQR] of 2.96 [1.84-3.29] months vs 3.37 [2.35-4.09] months, respectively). Increasing persistent PSA level was associated with an increased ACM risk (aHR, 1.14; 95% CI, 1.04-1.24; P = .004) and PCSM risk (aHR, 1.27; 95% CI, 1.12-1.45; P < .001).Conclusions and Relevance: PSA level assessed for at least 3 months after RP may minimize overtreatment, and in this study, a higher persistent PSA level was associated with a worse prognosis.
- 1 May 2025
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 11 (5) , 502
Open AccessPersistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk
Importance: Whether the conventional 1.5-month to 2.0-month time interval following radical prostatectomy (RP) for prostate cancer (PC) is sufficient to accurately document a persistent prostate-specific antigen (PSA) remains unanswered.Objective: To evaluate the time necessary to accurately document a persistent PSA level after RP.Design, Setting, and Participants: This cohort study evaluated whether a significant interaction existed between (1) a pre-RP PSA level greater than 20 ng/mL vs 20 ng/mL or less and (2) persistent PSA vs undetectable PSA after RP on PC-specific mortality (PCSM) risk and all-cause mortality (ACM) risk, adjusting for known PC prognostic factors, age at RP, year of RP, and the time-dependent use of post-RP radiation therapy (RT) and androgen deprivation therapy (ADT). Whether an increasing persistent PSA level was associated with a worse prognosis was also investigated. Patients with T1N0M0 to T3N0M0 PC treated with RP between 1992 and 2020 at 2 academic centers were included. Follow-up data were collected until November 2023. Data were analyzed from July 2024 to January 2025.Exposure: RP.Main Outcomes and Measures: Adjusted hazard ratio (aHR) of ACM and PCSM risk.Results: Of 30 461 patients included in the discovery cohort, the median (IQR) age was 64 (59-68) years; of 12 837 patients included in the validation cohort, the median (IQR) age was 59 (54-64) years. Compared with patients with undetectable PSA, among patients with persistent PSA, a pre-RP PSA level greater than 20 ng/mL vs 20 ng/mL or less was significantly associated with reduced ACM risk (aHR, 0.69; 95% CI, 0.51-0.91; P = .01; P for interaction < .001) and PCSM risk (aHR, 0.41; 95% CI, 0.25-0.66; P < .001; P for interaction = .02). This result remained after adjustment for prostate volume and was confirmed in the validation cohort for PCSM risk and may represent a higher proportion of patients with a pre-RP PSA greater than 20 ng/mL vs 20 ng/mL or less who could have reached an undetectable PSA level if additional time for PSA assessment occurred before initiating post-RP therapy for presumed persistent PSA. Notably, there was more frequent and a shorter median time to post-RP RT plus ADT or ADT use in patients with a pre-RP PSA greater than 20 ng/mL (244 of 446 [54.7%] at a median [IQR] of 2.68 [1.51-4.40] months) vs 20 ng/mL or less (338 of 972 [34.8%] at a median [IQR] of 3.30 [2.00-5.39] months). These treatment times were shorter than the times to an undetectable PSA in observed patients (median [IQR] of 2.96 [1.84-3.29] months vs 3.37 [2.35-4.09] months, respectively). Increasing persistent PSA level was associated with an increased ACM risk (aHR, 1.14; 95% CI, 1.04-1.24; P = .004) and PCSM risk (aHR, 1.27; 95% CI, 1.12-1.45; P < .001).Conclusions and Relevance: PSA level assessed for at least 3 months after RP may minimize overtreatment, and in this study, a higher persistent PSA level was associated with a worse prognosis.
- Open Access
- 2 July 2024
- Published by Elsevier in European Urology Oncology
- Vol. 7 (6) , 1520-1526
Mortality Risk for Patients with Biopsy Gleason Grade Group 1 Prostate Cancer
- 2 July 2024
- Published by Elsevier in European Urology Oncology
- Vol. 7 (6) , 1520-1526
Open AccessMortality Risk for Patients with Biopsy Gleason Grade Group 1 Prostate Cancer
- 1 October 2018
- Published by Elsevier in European Urology
- Vol. 74 (4) , 442-443
Eighteen Months of Androgen Deprivation Therapy in Men with High-risk Prostate Cancer and the Risk of Death
- 1 October 2018
- Published by Elsevier in European Urology
- Vol. 74 (4) , 442-443
Eighteen Months of Androgen Deprivation Therapy in Men with High-risk Prostate Cancer and the Risk of Death
- 23 August 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96 (4) , 778-784
Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer–Specific Mortality Stratified by the Extent of Competing Mortality
- 23 August 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96 (4) , 778-784
Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer–Specific Mortality Stratified by the Extent of Competing Mortality
- 1 June 2016
- Published by Elsevier in European Urology
- Vol. 69 (6) , 976-979
Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death
- 1 June 2016
- Published by Elsevier in European Urology
- Vol. 69 (6) , 976-979
Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death
- 1 June 2016
- Published by Elsevier in The Lancet Oncology
- Vol. 17 (6) , 687-688
Can short-term hormone therapy for rising PSA prolong survival?
- 1 June 2016
- Published by Elsevier in The Lancet Oncology
- Vol. 17 (6) , 687-688
Can short-term hormone therapy for rising PSA prolong survival?
- 1 May 2016
- Published by Elsevier in European Urology
- Vol. 69 (5) , 761-763
Is Gleason Grade 5 Prostate Cancer Resistant to Conventional Androgen Deprivation Therapy?
- 1 May 2016
- Published by Elsevier in European Urology
- Vol. 69 (5) , 761-763
Is Gleason Grade 5 Prostate Cancer Resistant to Conventional Androgen Deprivation Therapy?
- 10 April 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (11) , 1284
Reply to M.C. Scholz et al
- 10 April 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (11) , 1284
Reply to M.C. Scholz et al
- 10 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2_suppl) , 41
Comorbidity and androgen deprivation therapy use in men undergoing high-dose radiation for unfavorable intermediate- and high-risk prostate cancer.
41 Background: Despite evidence of prolonged survival when adding androgen deprivation therapy (ADT) to external beam radiation therapy (EBRT) in men with unfavorable intermediate- and high-risk prostate cancer (PC), some of these men are not receiving ADT. We explored whether comorbidity can explain this discrepancy given the observation that survival may be shortened in men with moderate to severe comorbidity who receive ADT. Methods: Between 10/1997 and 5/2013, 3,348 men with unfavorable intermediate- (2,380 patients; 70.7%) or high-risk (986 patients; 29.3%) PC were treated at the Prostate Cancer Foundation of Chicago using brachytherapy with or without neoadjuvant EBRT and/or ADT, and formed the study cohort. A multivariable logistic regression analysis was used to evaluate whether comorbidity (history of congestive heart failure [CHF] and/or myocardial infarction [MI]) was associated with decreased odds of ADT use in men with unfavorable intermediate- or high-risk PC, adjusting for age, PC prognostic factors, year of brachytherapy, and EBRT use. Results: Among patients with unfavorable-intermediate-risk PC, 31.2% received ADT, and in the high-risk cohort, 38.3%, 12.3%, and 4.8% received up to 6, >6-18, or >18 months of ADT respectively. In men with high-risk PC, a history of CHF/MI was not significantly associated with decreased odds of ADT use of any duration (all p values >0.71), but the odds of ADT use decreased over time (adjusted odds ratio (AOR) 0.87, 95% confidence interval (CI) [0.83,0.91], p6-18, and >18 months respectively, with no ADT as the reference). Similarly, in men with unfavorable intermediate-risk PC, a history of CHF/MI was not significantly associated with decreased odds of ADT use (p=0.49), whereas the odds of ADT use decreased significantly over time (AOR 0.96, 95% CI [0.94,0.98], p=0.0009). Conclusions: While ADT use has decreased over time in men with unfavorable intermediate- and high-risk PC undergoing brachytherapy with or without supplemental EBRT, this decrease does not appear to be occurring in men with a history of CHF or MI.
- 10 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2_suppl) , 41
Comorbidity and androgen deprivation therapy use in men undergoing high-dose radiation for unfavorable intermediate- and high-risk prostate cancer.
41 Background: Despite evidence of prolonged survival when adding androgen deprivation therapy (ADT) to external beam radiation therapy (EBRT) in men with unfavorable intermediate- and high-risk prostate cancer (PC), some of these men are not receiving ADT. We explored whether comorbidity can explain this discrepancy given the observation that survival may be shortened in men with moderate to severe comorbidity who receive ADT. Methods: Between 10/1997 and 5/2013, 3,348 men with unfavorable intermediate- (2,380 patients; 70.7%) or high-risk (986 patients; 29.3%) PC were treated at the Prostate Cancer Foundation of Chicago using brachytherapy with or without neoadjuvant EBRT and/or ADT, and formed the study cohort. A multivariable logistic regression analysis was used to evaluate whether comorbidity (history of congestive heart failure [CHF] and/or myocardial infarction [MI]) was associated with decreased odds of ADT use in men with unfavorable intermediate- or high-risk PC, adjusting for age, PC prognostic factors, year of brachytherapy, and EBRT use. Results: Among patients with unfavorable-intermediate-risk PC, 31.2% received ADT, and in the high-risk cohort, 38.3%, 12.3%, and 4.8% received up to 6, >6-18, or >18 months of ADT respectively. In men with high-risk PC, a history of CHF/MI was not significantly associated with decreased odds of ADT use of any duration (all p values >0.71), but the odds of ADT use decreased over time (adjusted odds ratio (AOR) 0.87, 95% confidence interval (CI) [0.83,0.91], p6-18, and >18 months respectively, with no ADT as the reference). Similarly, in men with unfavorable intermediate-risk PC, a history of CHF/MI was not significantly associated with decreased odds of ADT use (p=0.49), whereas the odds of ADT use decreased significantly over time (AOR 0.96, 95% CI [0.94,0.98], p=0.0009). Conclusions: While ADT use has decreased over time in men with unfavorable intermediate- and high-risk PC undergoing brachytherapy with or without supplemental EBRT, this decrease does not appear to be occurring in men with a history of CHF or MI.
- 10 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2_suppl) , 171
Gleason score and the risk of cause-specific and overall mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer.
171 Background: We evaluated whether a differential impact of adding 6 months of androgen deprivation (ADT) to radiation therapy (RT) on all-cause, prostate cancer-specific, and other-cause mortality (ACM, PCSM, OCM) in men with unfavorable-risk PC exists within Gleason score (GS) subgroups. Methods: Individual patient data from 743 men with unfavorable-risk PC from two randomized ADT trials were utilized. Competing risks and Cox regression were used to determine whether adding 6 months of ADT to RT significantly impacted PCSM, OCM and ACM within GS subgroups. Results: Men with GS 9,10 versus ≤ 8 were significantly more likely to be over 75 (23.3% versus 12.7%;p = 0.03). At a median follow-up of 11.9 and 11.8 years in the 683 and 60 patients with GS ≤ 8 and GS 9,10, 315 (46.1%) and 44 had died (73.1%), respectively. ADT in men with GS ≤ 8 was associated with significantly decreased ACM (Adjusted hazard ratio (AHR) 0.66; 95% confidence interval (CI): 0.52-0.82; p < 0.001) and PCSM (0.43; 0.28-0.66; p < 0.001) but was not associated with OCM (0.90; 0.68-1.17; p = 0.43). Among men with GS 9,10 PC, ADT significantly reduced PCSM (0.33; 0.11-0.99; p = 0.048) but not ACM (0.79; 0.38-1.61; p = 0.51) and increased OCM (2.16; 0.81-5.79; p = 0.12) resulting in opposite effects of ADT on OCM by GS subgroup (Table) such that the relative AHR of OCM in GS 9,10 versus ≤ 8 was nearly significantly increased (2.42; 0.87-6.71; p = 0.09). Conclusions: While ADT reduced PCSM for all men, survival was not prolonged in men with GS 9,10 due to ADT-driven increased OCM. This supports the hypothesis that older men with significant comorbidity may not experience prolonged survival when ADT is added to RT. [Table: see text]
- 10 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2_suppl) , 171
Gleason score and the risk of cause-specific and overall mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer.
171 Background: We evaluated whether a differential impact of adding 6 months of androgen deprivation (ADT) to radiation therapy (RT) on all-cause, prostate cancer-specific, and other-cause mortality (ACM, PCSM, OCM) in men with unfavorable-risk PC exists within Gleason score (GS) subgroups. Methods: Individual patient data from 743 men with unfavorable-risk PC from two randomized ADT trials were utilized. Competing risks and Cox regression were used to determine whether adding 6 months of ADT to RT significantly impacted PCSM, OCM and ACM within GS subgroups. Results: Men with GS 9,10 versus ≤ 8 were significantly more likely to be over 75 (23.3% versus 12.7%;p = 0.03). At a median follow-up of 11.9 and 11.8 years in the 683 and 60 patients with GS ≤ 8 and GS 9,10, 315 (46.1%) and 44 had died (73.1%), respectively. ADT in men with GS ≤ 8 was associated with significantly decreased ACM (Adjusted hazard ratio (AHR) 0.66; 95% confidence interval (CI): 0.52-0.82; p < 0.001) and PCSM (0.43; 0.28-0.66; p < 0.001) but was not associated with OCM (0.90; 0.68-1.17; p = 0.43). Among men with GS 9,10 PC, ADT significantly reduced PCSM (0.33; 0.11-0.99; p = 0.048) but not ACM (0.79; 0.38-1.61; p = 0.51) and increased OCM (2.16; 0.81-5.79; p = 0.12) resulting in opposite effects of ADT on OCM by GS subgroup (Table) such that the relative AHR of OCM in GS 9,10 versus ≤ 8 was nearly significantly increased (2.42; 0.87-6.71; p = 0.09). Conclusions: While ADT reduced PCSM for all men, survival was not prolonged in men with GS 9,10 due to ADT-driven increased OCM. This supports the hypothesis that older men with significant comorbidity may not experience prolonged survival when ADT is added to RT. [Table: see text]